PGxRx consulting offers pharmacogenomic reports in partnership with Innovative laboratories. These reports contain genetic health risk information that has not undergone FDA review. Utilizing advanced genotype data extracted from patient saliva DNA, our pharmacogenomic service aims to identify clinically relevant genetic variants that impact how medications are utilized based on individual health risks. It is essential to note that our service is not meant for disease diagnosis. Additionally, the interpretation of each report and its relevance may be influenced by a patient's ethnicity. The information delivered through our service is not intended for patients to independently make medical decisions. Instead, it serves to inform and provide genetic risk information to be shared directly with their licensed healthcare provider. Lastly, our pharmacogenomic reports do not provide any information about a patient's future risk of developing diseases.

PGxRx consulting utilizes genotyping data to identify medication risk factors, specifically variants associated with the metabolism of certain therapeutics. Our pharmacogenomic report then offers interpretive drug information, informing patients and facilitating discussions with healthcare professionals about the potential effects of these medications based on their genetic profile.

Warning: It is crucial to emphasize that pharmacogenomic test results should never be used to independently initiate, discontinue, or modify any treatment without first consulting with a patient's healthcare provider. The test results and their interpretation service are not a replacement for seeking medical advice from a qualified healthcare professional. Patients should always schedule an appointment and discuss the test results with their healthcare provider to make informed and appropriate decisions regarding their treatment plan.